NEW YORK, Oct. 9 - The National Heart, Lung, and Blood Institute today said it will spent $157 million over seven years to establish 10 centers for proteomics technology research.
So far approximately $22 million has been awarded to the centers for their first year of operation, according to the NHLBI, part of the US National Institutes of Health.
The initiative's proteomics centers were established at The Institute for Systems Biology,
Each center will focus on developing different types of proteomics technology related to studying the normal and diseased heart, lung, blood and sleep process, according to the NHLBI. Research will include the study of protein profiling, post-translation modifications, and protein-protein interactions.
"These awards take an important step beyond the science of gene research," NHLBI director Claude Lenfant said in a statement. "Research at the level of the gene cannot provide a full picture of what's going on within a cell. These state-of-the-art centers will help supply that missing information and so advance biomedical research and clinical care."
A web site to provide information about the centers' activities is in the works, and new information, techniques, and products such as reagents developed at the centers will be made available to other scientists, said Susan Old, NHLBI proteomic program administrator.
"The new initiative provides the kind of sustained support needed for scientists to develop innovative technologies," said Old. "The centers also will be encouraged to share ideas and thus spur research even more."
The proteomics centers were established as the NHLBI Proteomics Center at The Institute for Systems Biology in Seattle; the NHLBI Proteomics Center at Yale University; the Proteomic Analysis of Blood Components in Autoimmune Disease at Stanford University; the Proteomics of Adaptation to Ischemia/Hypoxia in the Heart, Lung, and Blood at The Johns Hopkins University School of Medicine; the Oxidative Protein Modifications in Cardiovascular Disease at Boston University; the Development of Novel Mass Spectrometry Tools for Individual Cell Proteome Analysis at the Medical College of Wisconsin in Milwaukee; the Cardiovascular Proteomics Center at the Medical University of South Carolina in Charleston; the Three-D Proteomics and Aptemeric Arrays for Cystic Fibrosis at the Henry M. Jackson Foundation for the Advancement of Military Medicine, in Rockville, Md.; the Southwestern Center for Proteomics Research at the University of Texas Southwestern Medical Center in Dallas; and the Proteomic Technologies to Study Airway Inflammation at the University of Texas Medical Branch at Galveston.